This is a preview of subscription content, log in via an institution to check access.
Reference
Seal BS, et al. Cost-effectiveness of regorafenib for pretreated metastatic colorectal cancer patients in the United States. 2013 Gastrointestinal Cancers Symposium : abstr. 578, 24 Jan 2013. Available from: URL: http://gicasym.asco.org/content/106193-133
Rights and permissions
About this article
Cite this article
Costs of regorafenib in pretreated mCRC justified?. PharmacoEcon Outcomes News 671, 5 (2013). https://doi.org/10.1007/s40274-013-0129-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0129-8